{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:33:50Z","timestamp":1789194830129,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008386","name":"Marmara University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immunoglobulin G replacement therapy (IgRT), intravenous (IV) and subcutaneous (SC) routes, is pivotal in treatment of primary immunodeficiencies (PID). In recent years, facilitated subcutaneous immunoglobulin (fSCIG), a combination of rHuPH20 and 10% IgG has emerged as a delivery method to combine advantages of both IV and SC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>In an observational prospective cohort, we investigated patient experience with fSCIG in PID patients from 5 PID centers for up to 12\u00a0months. We assessed the efficacy and safety of this treatment with patient\/caregiver- and physician-reported indicators. Additionally, we analyzed patient treatment satisfaction (TSQM-9) and quality of life (QoL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We enrolled 29 patients (22 pediatric and 7 adults; 14 females and 15 males; (median: 15, min\u2013max: 2\u201340.9\u00a0years) who initiated fSCIG as IgRT-naive (n\u2009=\u20091), switched from conventional rapid-push 10% SCIG (n\u2009=\u20096) or IVIG (n\u2009=\u200922). Among the participants, 19 (65%) exhibited antibody deficiencies, 8 (27%) combined immunodeficiencies, and 2 (7%) immune dysregulations. Remarkably, targeted trough immunoglobulin G levels were achieved under all previous IgRTs as well as fSCIG. No severe systemic adverse drug reactions were documented, despite prevalent local (%86.45) and mild systemic (%26.45) adverse reactions were noted with fSCIG. Due to mild systemic symptoms, 2 patients switched from fSCIG to 10% SCIG. The patient satisfaction survey revealed a notable increase at 2-4th (p\u2009=\u20090.102); 5-8th (p\u2009=\u20090.006) and 9-12th (p\u2009&lt;\u20090.001) months compared to the baseline. No significant trends were observed in QoL surveys.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>fSCIG demonstrates admissable tolerability and efficacy in managing PIDs in addition to notable increase of patients\u2019 drug satisfaction with IgRT. The identified benefits support the continuation of this therapy despite the local reactions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10875-024-01771-0","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T01:01:46Z","timestamp":1722819706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort"],"prefix":"10.1007","volume":"44","author":[{"given":"Ezgi","family":"Yalcin Gungoren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek","family":"Yorgun Altunbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummugulsum","family":"Dikici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Meric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isil","family":"Eser Simsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayca","family":"Kiykim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Karabiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalan","family":"Yakici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazil","family":"Orhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk","family":"Cokugras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metin","family":"Aydogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oner","family":"Ozdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Bilgic Eltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Baris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Karakoc-Aydiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"issue":"6","key":"1771_CR1","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s10875-012-9740-x","volume":"32","author":"RL Wasserman","year":"2012","unstructured":"Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J Clin Immunol. 2012;32(6):1153\u201364.","journal-title":"J Clin Immunol"},{"issue":"4","key":"1771_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.iac.2008.07.001","volume":"28","author":"M Garcia-Lloret","year":"2008","unstructured":"Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol Allergy Clin North Am. 2008;28(4):833\u201349.","journal-title":"Immunol Allergy Clin North Am."},{"issue":"1","key":"1771_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.5152\/TurkPediatriArs.2016.3058","volume":"51","author":"E KarakocAydiner","year":"2016","unstructured":"KarakocAydiner E, Kiykim A, Baris S, Ozen A, Barlan I. Use of subcutaneous immunoglobulin in primary immune deficiencies. Turk Pediatri Ars. 2016;51(1):8\u201314.","journal-title":"Turk Pediatri Ars"},{"issue":"6","key":"1771_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jaci.2008.08.033","volume":"122","author":"FA Bonilla","year":"2008","unstructured":"Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008;122(6):1238\u20139.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1771_CR5","first-page":"514","volume":"21","author":"S Baris","year":"2011","unstructured":"Baris S, Ercan H, Cagan HH, Ozen A, Karakoc-Aydiner E, Ozdemir C, et al. Efficacy of intravenous immunoglobulin treatment in children with common variable immunodeficiency. J Investig Allergol Clin Immunol. 2011;21(7):514\u201321.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"3","key":"1771_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.24953\/turkjped.2020.03.004","volume":"62","author":"E Nain","year":"2020","unstructured":"Nain E, Kiykim A, Kasap NA, Baris S, Ozen A, Aydiner EK. Immediate adverse reactions to intravenous immunoglobulin in primary immune deficiencies: a single center experience. Turk J Pediatr. 2020;62(3):379\u201386.","journal-title":"Turk J Pediatr"},{"issue":"1","key":"1771_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clim.2004.02.002","volume":"112","author":"M Berger","year":"2004","unstructured":"Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112(1):1\u20137.","journal-title":"Clin Immunol"},{"issue":"2","key":"1771_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00063030-200721020-00005","volume":"21","author":"A Gardulf","year":"2007","unstructured":"Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21(2):105\u201316.","journal-title":"BioDrugs"},{"issue":"2","key":"1771_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1081-1206(10)60197-4","volume":"101","author":"ML Moore","year":"2008","unstructured":"Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101(2):114\u201321.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"Suppl 1","key":"1771_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2249.2009.04027.x","volume":"158 Suppl 1","author":"S Misbah","year":"2009","unstructured":"Misbah S, Sturzenegger MH, Borte M, Shapiro RS, Wasserman RL, Berger M, et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin Exp Immunol. 2009;158 Suppl 1(Suppl 1):51\u20139.","journal-title":"Clin Exp Immunol."},{"issue":"8","key":"1771_CR11","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2165\/11209490-000000000-00000","volume":"72","author":"PL McCormack","year":"2012","unstructured":"McCormack PL. Immune globulin subcutaneous (human) 20%: in primary immunodeficiency disorders. Drugs. 2012;72(8):1087\u201397.","journal-title":"Drugs"},{"key":"1771_CR12","doi-asserted-by":"crossref","unstructured":"Wasserman RL, HyQvia Experience Study G. Clinical Practice Experience with HyQvia in Adults Using Alternative Dosing Regimens and Pediatric Patients: A Retrospective Study. Adv Ther. 2020;37(4):1536\u201349.","DOI":"10.1007\/s12325-020-01264-7"},{"issue":"7","key":"1771_CR13","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s10875-022-01352-z","volume":"42","author":"A Bousfiha","year":"2022","unstructured":"Bousfiha A, Moundir A, Tangye SG, Picard C, Jeddane L, Al-Herz W, et al. The 2022 Update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity. J Clin Immunol. 2022;42(7):1508\u201320.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1771_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jaip.2022.10.003","volume":"11","author":"S Baris","year":"2023","unstructured":"Baris S, Abolhassani H, Massaad MJ, Al-Nesf M, Chavoshzadeh Z, Keles S, et al. The Middle East and North Africa Diagnosis and Management Guidelines for Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2023;11(1):158-80 e11.","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"5","key":"1771_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1023\/A:1008853819715","volume":"7","author":"U Ravens-Sieberer","year":"1998","unstructured":"Ravens-Sieberer U, Bullinger M. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results. Qual Life Res. 1998;7(5):399\u2013407.","journal-title":"Qual Life Res"},{"issue":"11","key":"1771_CR16","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1681\/ASN.V5111888","volume":"5","author":"WG Couser","year":"1995","unstructured":"Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol. 1995;5(11):1888\u201394.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1771_CR17","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0895-4356(98)00106-1","volume":"51","author":"B Gandek","year":"1998","unstructured":"Gandek B, Ware JE Jr, Aaronson NK, Alonso J, Apolone G, Bjorner J, et al. Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):1149\u201358.","journal-title":"J Clin Epidemiol."},{"key":"1771_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1471-2458-6-247","volume":"6","author":"Y Demiral","year":"2006","unstructured":"Demiral Y, Ergor G, Unal B, Semin S, Akvardar Y, Kivircik B, et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health. 2006;6:247.","journal-title":"BMC Public Health"},{"issue":"1","key":"1771_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/09638288.2020.1762768","volume":"44","author":"F Ozden","year":"2022","unstructured":"Ozden F, Karaman ON, Tugay N, Savas O, Sozen T, Ucuncu H. The reliability and validity of the Turkish version of the Facial Disability Index. Disabil Rehabil. 2022;44(1):148\u201357.","journal-title":"Disabil Rehabil"},{"key":"1771_CR20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"key":"1771_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"1771_CR22","first-page":"228","volume":"9","author":"SB Eltan","year":"2022","unstructured":"Eltan SB, Keskin O, Deveci MF. Safety, efficiency, and treatment satisfaction in children with primary immunodeficiency receiving subcutaneous immunoglobulin treatment. North Clin Istanb. 2022;9(3):228\u201334.","journal-title":"North Clin Istanb"},{"key":"1771_CR23","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3389\/fimmu.2020.00981","volume":"11","author":"E Wiesik-Szewczyk","year":"2020","unstructured":"Wiesik-Szewczyk E, Soldacki D, Paczek L, Jahnz-Rozyk K. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies. Front Immunol. 2020;11:981.","journal-title":"Front Immunol"},{"issue":"6","key":"1771_CR24","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10875-023-01470-2","volume":"43","author":"M Borte","year":"2023","unstructured":"Borte M, Hanitsch LG, Mahlaoui N, Fasshauer M, Huscher D, Speletas M, et al. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study. J Clin Immunol. 2023;43(6):1259\u201371.","journal-title":"J Clin Immunol"},{"issue":"2","key":"1771_CR25","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2217\/imt-2021-0167","volume":"14","author":"U Baumann","year":"2022","unstructured":"Baumann U, Fasshauer M, Pausch C, Wittkowski H, Hermann C, Pittrow D, et al. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases. Immunotherapy. 2022;14(2):135\u201343.","journal-title":"Immunotherapy"},{"issue":"12","key":"1771_CR26","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2217\/imt-2017-0092","volume":"9","author":"RL Wasserman","year":"2017","unstructured":"Wasserman RL. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases. Immunotherapy. 2017;9(12):1035\u201350.","journal-title":"Immunotherapy"},{"issue":"6","key":"1771_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.2217\/imt-2023-0305","volume":"16","author":"M Mach-Tomalska","year":"2024","unstructured":"Mach-Tomalska M, Pituch-Noworolska A, Bien E, Malanowska M, Machura E, Pukas-Bochenek A, et al. Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases. Immunotherapy. 2024;16(6):391\u2013403.","journal-title":"Immunotherapy"},{"issue":"3","key":"1771_CR28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10238-020-00633-4","volume":"20","author":"F Angelotti","year":"2020","unstructured":"Angelotti F, Capecchi R, Giannini D, Mazzarella O, Rocchi V, Migliorini P. Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(((R)))) in immunodeficiency diseases: real-life data from a monocentric experience. Clin Exp Med. 2020;20(3):387\u201392.","journal-title":"Clin Exp Med"},{"issue":"4","key":"1771_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s40259-014-0104-3","volume":"28","author":"M Sanford","year":"2014","unstructured":"Sanford M. Human immunoglobulin 10 % with recombinant human hyaluronidase: replacement therapy in patients with primary immunodeficiency disorders. BioDrugs. 2014;28(4):411\u201320.","journal-title":"BioDrugs"},{"issue":"10","key":"1771_CR30","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/imt-2016-0066","volume":"8","author":"RL Wasserman","year":"2016","unstructured":"Wasserman RL, Melamed I, Kobrynski L, Puck J, Gupta S, Doralt J, et al. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy. 2016;8(10):1175\u201386.","journal-title":"Immunotherapy"},{"issue":"18","key":"1771_CR31","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.3390\/cancers15184524","volume":"15","author":"M Dimou","year":"2023","unstructured":"Dimou M, Speletas M, Milito C, Pyzik A, Huscher D, Kamieniak M, et al. Insights into facilitated subcutaneous immunoglobulin use in patients with secondary immunodeficiency diseases: A FIGARO subgroup analysis. Cancers (Basel). 2023;15(18):4524.","journal-title":"Cancers (Basel)."},{"issue":"7354","key":"1771_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature10134","volume":"475","author":"RM Anthony","year":"2011","unstructured":"Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature. 2011;475(7354):110\u20133.","journal-title":"Nature"},{"issue":"1","key":"1771_CR33","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/curroncol30010022","volume":"30","author":"A Visentin","year":"2022","unstructured":"Visentin A, Molinari MC, Pravato S, Cellini A, Angotzi F, Cavaretta CA, et al. A retrospective study on the efficacy of subcutaneous immunoglobulin as compared to intravenous formulation in patients with chronic lymphocytic leukemia and secondary antibody deficiency. Curr Oncol. 2022;30(1):274\u201383.","journal-title":"Curr Oncol"},{"issue":"1","key":"1771_CR34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13223-022-00746-3","volume":"18","author":"R Mallick","year":"2022","unstructured":"Mallick R, Solomon G, Bassett P, Zhang X, Patel P, Lepeshkina O. Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes. Allergy Asthma Clin Immunol. 2022;18(1):110.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-024-01771-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01771-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:42:02Z","timestamp":1730436122000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-024-01771-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1771"],"URL":"https:\/\/doi.org\/10.1007\/s10875-024-01771-0","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,5]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Marmara University, School of Medicine (09.2021.1234).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Informed consent for participation was obtained from all individuals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Informed publication consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"EK-A., E.Y.G., M.Y.A., U.D., Z.M., I.E.S., A.K., S.C., E.K., N.Y., F.O., H.C., M.A., O.O., S.B.E., S.B., A.O. have no conflict of interest to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"169"}}